Hadjivassiliou M. Immune-mediated acquired ataxias. Handb Clin Neurol. 2012;103:189–99.

Article  PubMed  Google Scholar 

Mitoma H, Adhikari K, Aeschlimann D, Chattopadhyay P, Hadjivassiliou M, Hampe CS, et al. Consensus paper: neuroimmune mechanisms of cerebellar ataxias. Cerebellum. 2016;15(2):213–32.

Article  CAS  PubMed  Google Scholar 

Mitoma H, Hadjivassiliou M, Honnorat J. Guidelines for treatment of immune-mediated cerebellar ataxias. Cerebellum Ataxias. 2015;2:14.

Article  PubMed  PubMed Central  Google Scholar 

Joubert B, Rotásky J, Honnorat J. Nonparaneoplastic autoimmune cerebellar ataxia. Handb Clin Neurol. 2018;155:313–32.

Article  PubMed  Google Scholar 

Hadjivassiliou M, Mitoma H, Manto M. Autoimmune ataxia. In: Mitoma H, Manto M, editors. Neuroimmune diseases; from cells to the living brain. Springer Nature; 2019. p. 599–620.

Chapter  Google Scholar 

Mitoma H, Manto M, Hadjivassiliou M. Immune-mediated cerebellar ataxias: clinical diagnosis and treatment based on immunological and physiological mechanisms. J Mov Disord. 2021;14(1):10–28.

Article  PubMed  PubMed Central  Google Scholar 

Hadjivassiliou M, Graus F, Honnorat J, Jarius S, Titulaer M, Manto M, Hoggard N, Sarrigiannis P, Mitoma H. Diagnostic criteria for primary autoimmune cerbellar ataxia (PACA)-guidlines from an International Task Force on Immune Mediated Cerbellar Ataxia. Cerebellum. 2020;19(4):605–10.

Article  PubMed  PubMed Central  Google Scholar 

Nanri K, Niwa H, Mitoma H, Takei A, Ikeda J, Harada T, et al. Low-titer anti-GAD-antibody-positive cerebellar ataxia. Cerebellum. 2013;12(2):171–5.

Article  CAS  PubMed  Google Scholar 

Baizabal-Carvallo JF, Alonso-Juarez M. Cerebellar disease associated with anti-glutamic acid decarboxylase antibodies: review. A J Neural Transm (Vienna). 2017;124(10):1171–82.

Article  CAS  PubMed  Google Scholar 

Petrijan T, Menih M. Low-Titre GAD Antibody-associated late-onset cerebellar ataxia with a significant clinical response to intravenous immunoglobulin treatment. Cerebellum. 2017;16(4):868–71.

Article  CAS  PubMed  Google Scholar 

Muñiz-Castrillo S, Vogrig A, Joubert B, Pinto AL, Gonçalves D, Chaumont H, et al. Transient neurological symptoms preceding cerebellar ataxia with glutamic acid decarboxylase antibodies. Cerebellum. 2020;19(5):715–21.

Article  PubMed  Google Scholar 

Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes. 1993;42(2):359–62.

Article  CAS  PubMed  Google Scholar 

Stenström G, Gottsäter A, Bakhtadze E, Berger B, Sundkvist G. Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment. Diabetes. 2005;54(Suppl 2):S68–72.

Article  PubMed  Google Scholar 

Yasui J, Kawasaki E, Tanaka S, Awata T, Ikegami H, Imagawa A, et al. Clinical and genetic characteristics of non-insulin-requiring glutamic acid decarboxylase (GAD) autoantibody-positive diabetes: a nationwide survey in Japan. PLoS One. 2016;11:e0155643.

Article  PubMed  PubMed Central  Google Scholar 

Huang G, Yin M, Xiang Y, Li X, Shen W, Luo S, et al. Persistence of glutamic acid decarboxylase antibody (GADA) is associated with clinical characteristics of latent autoimmune diabetes in adults: a prospective study with 3-year follow-up. Diabetes Metab Res Rev. 2016;32(6):615–22.

Article  CAS  PubMed  Google Scholar 

Carlsson S. Etiology and pathogenesis of latent autoimmune diabetes in adults (LADA) compared to type 2 diabetes. Front Physiol. 2019;10:320.

Article  PubMed  PubMed Central  Google Scholar 

Mitoma H, Buffo A, Gelfo F, Guell X, Fucà E, Kakei S, et al. Consensus paper. Cerebellar reserve: from cerebellar physiology to cerebellar disorders. Cerebellum. 2019;19(1):131–53.

Article  PubMed Central  Google Scholar 

Graus F, Saiz A, Dalmau J. GAD antibodies in neurological disorders-insights and challenges. Nat Rev Neurol. 2020;16:353–65.

Article  CAS  PubMed  Google Scholar 

Kikuchi A, Yoneda M, Hasegawa T, Matsunaga A, Ikawa M, Nakamura T, et al. High prevalence of serum anti-NH2-terminal α-enolase antibodies un patients with multiple system atrophy and corticobasal syndrome. J Neurol. 268(11):4291–5.

Siddiqui TG, Whitfield T, Praharaju SJ, Sadiq D, Kazmi H, Ben-Joseph A, et al. Magnetic resonance imaging in stable mild cognitive impairment, prodromal Alzheimer’s disease, and prodromal dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2020;49(6):583–8.

Article  PubMed  Google Scholar 

Lavan O, Apter A, Benaroya-Milshtein N, Fennig S. The prodrome of psychotic disorders. Harefuah. 2021;160(2):104–9.

PubMed  Google Scholar 

Chen CC, Yao NW, Lin CW, Su WS, Wu CT, Chang C, et al. Neuroimaging spectrum at pre-, early, and late symptomatic stages of SCA 17 mice. Cerebellum. 2020;19(4):487–500.

Article  CAS  PubMed  Google Scholar 

Velázquez-Pérez L, Rodriguez-Labrada R, González-Garcés Y, Arrufat-Pie E, Torres-Vega R, Medrano-Montero J, et al. Prodromal spinocerebellar ataxia type 2 subjects have quantifiable gait and postural sway deficits. Mov Disord. 2021;36(2):471–80.

Article  PubMed  Google Scholar 

de Oliveira CM, Leotti VB, Bolzan G, Cappelli AH, Rocha AG, Ecco G, et al. Pre-ataxic changes of clinical scales and eye movement in Machado-Joseph disease: BIGPRO study. Mov Disord. 2021;36(4):985–94.

Article  PubMed  Google Scholar 

Jacobi H, du Montcel ST, Romanzetti S, Harmuth F, Mariotti C, Nanetti L, et al. Conversion of individuals at risk for spinocerebellar ataxia type 1,2,3,and 6 to manifest ataxia (RISCA): longitudinal cohort study. Lancet Neurol. 2020;19(9):738–47.

Article  CAS  PubMed  Google Scholar 

Kobayashi T, Tamemoto K, Nakanishi K, Kato N, Okubo M, Kajio H, et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care. 1993;16(5):780–8.

Article  CAS  PubMed  Google Scholar 

Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M, et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med. 1994;118(3):299–303.

Article  Google Scholar 

Nociti V, Frisullo G, Tartaglione T, Patanella AK, Iorio R, Tonali PA, et al. Refractory generalized seizures and cerebellar ataxia associated with anti-GAD antibodies responsive to immunosuppressive treatment. Eur J Neurol. 2010;17(1):e5.

Article  CAS  PubMed  Google Scholar 

Virgilio R, Corti S, Agazzi P, Santoro D, Lanfranconi S, Candelise L, et al. Effect of steroid treatment in cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies. J Neurol Neurosurg Psychiatry. 2009;80(1):95–6.

Article  CAS  PubMed  Google Scholar 

Sunwoo JS, Chu K, Byun JI, Moon J, Lim JA, Kim TJ, Lee ST, Jung KH, Park KI, Jeon D, Jung KY, Kim M, Lee SK. Intrathecal-specific glutamic acid decarboxylase antibodies at low titers in autoimmune neurological disorders. J Neuroimmunol. 2016;290:15–21.

Article  CAS  PubMed  Google Scholar 

Ariño H, Gresa-Arribas N, Blanco Y, Martínez-Hernández E, Sabater L, Petit-Pedrol M, Rouco I, Bataller L, Dalmau JO, Saiz A, Graus F. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy. JAMA Neurol. 2014;71(8):1009–16.

Article  PubMed  PubMed Central  Google Scholar 

Mitoma H, Manto M, Hampe CS. Pathogenic roles of glutamic acid decarboxylase 65 autoantibodies in cerebellar ataxias. J Immunol Res. 2017;2017:2913297.

Article  PubMed  PubMed Central  Google Scholar 

Baizabal-Carvallo JF. The neurological syndromes associated with glutamic acid decarboxylase antibodies. J Autoimmun. 2019;101:35–47.

Article  CAS  PubMed  Google Scholar 

Matsumoto S, Kusuhara T, Nakajima M, Ouma S, Takahashi M, Yamada T. Acute attacks and brain stem signs in a patient with glutamic acid decarboxylase autoantibodies. J Neurol Neurosurg Psychiatry. 2002;73(3):345–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muñiz-Castrillo S, Vogrig A, Montagnac C, Joubert B, Benaiteau M, Casez O, et al. Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based study. J Neurol. 2021; https://doi.org/10.1007/s00415-021-10424-w.

Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olesen H, De Camilli P. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature. 1990;347(6289):151–6.

Article  ADS  CAS  PubMed  Google Scholar 

Daw K, Powers AC. Two distinct glutamic acid decarboxylase auto-antibody specificities in IDDM target different epitopes. Diabetes. 1995;44(2):216–20.

Article  CAS  PubMed  Google Scholar 

Powers AC, Bavik K, Tremble J, Daw K, Scherbaum WA, Banga JP. Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders. Clin Exp Immunol. 1999;118(3):349–56.

Article  CAS  PubMed  PubMed Central